seen from United States
seen from United States
seen from United States
seen from Venezuela
seen from United States
seen from Japan
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from Russia
seen from China
seen from Colombia
seen from United States
seen from United States
seen from United States
Machine Learning Makes Drug Repurposing for Psychiatric Disorders More Effective
Focusing on genes associated with psychiatric and neurological disorders, and drugs approved for use in other diseases, a new AI system can increase the effectiveness of drug repurposing.
Common Blood Pressure Medication Strips Tumors of Immune Shield: what it means
Because telmisartan is already FDA-approved, it could potentially be repurposed to boost existing cancer immunotherapies much faster than developing fresh drugs from scratch. Laboratory tests showed the drug depleted PD-L1 in breast, colon, and ovarian cancer cells without harming healthy immune cells. The findings suggest this common heart medication might help unmask stubborn tumors, making them vulnerable to the body's natural defenses. Researchers have discovered that telmisartan, a widely prescribed medication for high blood pressure, can strip cancer cells of a critical defense mechanism that supports them hide from the immune system. The drug targets PD-L1, a protein that acts like an invisibility cloak on tumor surfaces, preventing immune cells from recognizing and attacking cancer. Unlike seven similar blood pressure medications tested, telmisartan uniquely triggers the destruction of this shield protein through a process that tags it for cellular garbage disposal.
https://jitc.bmj.com/content/14/3/e012426
Study Mines Veteran Health Data to Find Drugs That May Extend ALS Survival
Researchers have mined one of the largest collections of medical records for amyotrophic lateral sclerosis (ALS) to hunt for existing drugs that might help patients live longer. The team, led by Lawrence Livermore National Laboratory, analyzed health data from over 11,000 U.S. military veterans diagnosed with ALS between 2009 and 2019. Using artificial intelligence combined with rigorous statistical methods designed to mimic controlled experiments, the scientists evaluated 162 different medications. They identified 27 drugs already approved for other conditions that showed statistically significant associations with survival changes in ALS patients. The research arrives as traditional drug development for ALS faces setbacks, including the recent withdrawal of the treatment Relyvrio after it failed to prove effective in larger trials. Because ALS became a service-connected disease for veterans in 2009, the Veterans Health Administration built an unusually detailed decade-long treatment record, creating a unique opportunity for this kind of analysis. The work, published in The Lancet Digital Health and conducted with Stanford, VA Palo Alto, and UCLA, offers a new pathway for finding treatments by repurposing medications already sitting on pharmacy shelves.
A Lawrence Livermore National Laboratory (LLNL)-led team of scientists and computational engineers has identified several existing medicatio
World Health Organization has classified Pseudomonas aeruginosa as one of top priority threat in terms of the prevailing pandemic scenario of antibiotic-resistant superbugs. This pathogen is widespread in healthcare settings and is listed as one of the top three nosocomial infectious agents. A susceptible population is vulnerable due to lack of vaccine availability to combat this opportunistic pathogen. Pyocyanin (PCN) is considered as a prime virulence factor of P. aeruginosa among many others. A wide range of bioactivities have been attributed to this compound primarily based on is redox active nature. We attempted to exploit structural information of PCN in order to screen available drug pool for disrupting or reducing PCN production. In this proof of concept study, PCN molecule’s structure was studied for a potential drug hit via studying chemical-protein interaction (CPI). The CPI data was used to identify query-drug interactions. A screening was performed and high probability hits were selected. The predicted targets were tested for inhibition of PCN production. Piperaquine showed remarkable inhibition of PCN biosynthesis. This predicted reported target may provide a basis for the development of a reliable anti-virulence drug against acute and urinary tract infections by P. aeruginosa. The approach adopted here could be extended to other bacterial pathogens for potential immunogenic target predictions and ultimately successful drug development.
Un nuovo metodo accelera la scoperta di farmaci da anni a mesi: innovazioni e implicazioni cliniche
Introduzione La scoperta di nuovi farmaci è un processo lungo e complesso, che può richiedere anni di ricerca e sviluppo prima che un farmaco potenziale possa essere testato clinicamente e infine approvato per l’uso terapeutico. Questo processo tradizionalmente lungo è caratterizzato da numerosi passaggi, tra cui la scoperta di molecole, la convalida di bersagli, l’ottimizzazione del composto, i…
Network-based drug repurposing for the treatment of COVID-19 patients in different clinical stages. Wang et al., Heliyon. 2023 Feb 24 : e14059.
La proteina S100B: il fattore infiammatorio della sclerosi multipla che ha già molecole dedicate allo scopo
La proteina S100B: il fattore infiammatorio della sclerosi multipla che ha già molecole dedicate allo scopo
S100B è una piccola proteina legante ioni calcio e zinco, sintetizzata principalmente dagli astrociti nel sistema nervoso e, in misura minore, dagli oligodendrociti. Esercita sia azioni intracellulari che extracellulari. Sebbene non sia stata delineata una funzione intracellulare chiara e univoca per questa proteina, si ritiene che la S100B secreta dagli astrociti agisca come un fattore di…
View On WordPress
The SARS-CoV-2 targeted human RNA binding proteins network biology to investigate COVID-19 associated manifestations. Prasad, et al., International journal of biological macromolecules doi: 10.1016/j.ijbiomac.2022.07.200.
